Insights into Chagas treatment based on the potential of bacteriocin AS-48 by Martín-Escolano, Rubén et al.
Contents lists available at ScienceDirect
IJP: Drugs and Drug Resistance
journal homepage: www.elsevier.com/locate/ijpddr
Insights into Chagas treatment based on the potential of bacteriocin AS-48
Rubén Martín-Escolanoa, Rubén Cebriánb,1, Javier Martín-Escolanoa, Maria J. Rosalesa,
Mercedes Maquedab, Manuel Sánchez-Morenoa, Clotilde Marína,∗
a Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa S/n, E-
18071, Granada, Spain
bDepartment of Microbiology, Faculty of Sciences. C/ Fuentenueva S/n. University of Granada, Severo Ochoa /n, 18071, Granada, Spain







A B S T R A C T
Chagas disease caused by the protozoan parasite Trypanosoma cruzi represents a significant public health pro-
blem in Latin America, affecting around 8 million cases worldwide. Nowadays is urgent the identification of new
antichagasic agents as the only therapeutic options available, Nifurtimox and Benznidazole, are in use for> 40
years, and present high toxicity, limited efficacy and frequent treatment failures in the chronic phase of the
disease. Recently, it has been described the antiparasitic effect of AS-48, a bacteriocin produced by Enterococcus
faecalis, against Trypanosoma brucei and Leishmania spp. In this work, we have demonstrated the in vitro potential
of the AS-48 bacteriocin against T. cruzi. Interesting, AS-48 was more effective against the three morphological
forms of different T. cruzi strains, and displayed lower cytotoxicity than the reference drug Benznidazole. In
addition, AS-48 combines the criteria established as a potential antichagasic agent, resulting in a promising
therapeutic alternative. According to the action mechanism, AS-48 trypanocidal activity could be explained in a
mitochondrion-dependent manner through a reactive oxygen species production and mitochondrial depolar-
ization, causing a fast and severe bioenergetic collapse.
1. Introduction
Chagas disease (CD) caused by the flagellated protozoan
Trypanosoma cruzi and transmitted by a triatomine insect is a neglected
tropical disease endemic in Latin America. It is estimated that around 8
million people are infected worldwide and more than 28 million are
living at risk of infection (WHO, 2016). The parasites can adopt three
different morphological forms along their life cycle depending on the
interaction with the host: i) epimastigote (the proliferative insect vector
born stage), ii) trypomastigote (the infective, non-proliferative form)
and iii) amastigote (intracellular proliferative form) (Adade et al.,
2013). The main drugs used for the treatment of CD are Benznidazole
(BZN, Rochagan®, Radanil®, Roche) and Nifurtimox (NFX, Lampit®,
Bayer), which are ineffective in the chronic phase of the disease and
present significant side effects (Adade et al., 2013). To this must be
added the existence of strains resistant to these drugs, that hinders the
disease treatment (Wilkinson et al., 2008; Mejia et al., 2012; Campos
et al., 2014). For this reason, it is urgent to identify and develop novel
active drugs against new targets, with low toxicity and high tolerance in
patients, being effective in both, acute and chronic phase of the
infection.
Resistance to antimicrobial compounds is a global phenomenon
headed by bacteria. Because of this, antimicrobial peptides (AMPs)
have been rediscovered for their potential use in the treatment of
multidrug-resistant bacteria (Yu et al., 2016; Mishra et al., 2017; Lázár
et al., 2018). AMPs can be defined as a ubiquitous and diverse group of
natural compounds produced by all living organisms as a part of their
innate defense system, that display antimicrobial activity against pa-
thogen organism (Adermann et al., 2014; Smith and Dyrynda, 2015;
Chung and Khanum, 2017; Kubicek-Sutherland et al., 2017). They are
gaining attention in recent years due to their fast mode of action against
a broad spectrum of pathogen microorganism and low capacity to
generate resistance. The AMPs produced by bacteria are called bac-
teriocins. They are ribosomally synthesized peptides with antimicrobial
activities (Hassan et al., 2012; Cotter et al., 2013). The mechanism of
action is primarily based on the disruption of the cell membranes, al-
though other mechanisms of action have been described (Prince et al.,
2016). Due to the high specificity that they generally present towards
the membranes of bacteria, in general, they present low toxicity and
have been proposed as promising candidates for clinical and veterinary
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use (Montalbán-López et al., 2011). Although their potential in the
control of pathogenic bacteria is well documented, in the case of
parasites not many studies are available. In fact, in the scientific lit-
erature there are some examples of AMPs with activity against T. cruzi
either in vitro or in vivo (Amino et al., 2002; Jacobs et al., 2003; Fieck
et al., 2010; Shin et al., 2016; Mello et al., 2017), however, to date, no
bacteriocins with antiparasitic activity have been described.
One of the most exciting and well-known bacteriocin is the circular
enterocin AS-48. It is a 70-residue, head-to-tail joined, amphipathic and
cationic bacteriocin produced by different Enterococcus species
(Maqueda et al., 2004) with a broad bactericidal activity against both
Gram-positive and Gram-negative disease-associated pathogens (Gálvez
et al., 1989; Aguilar-Pérez et al., 2018; Cebrián et al., 2018; Perales-
Adán et al., 2018). The most distinctive structural feature of AS-48 is its
circular structure and its amphipathicity, which contributes to a re-
markable stability in a broad range of temperature and pH (Maqueda
et al., 2004; Montalbán-López et al., 2011; Sánchez-Hidalgo et al.,
2011). In addition, AS-48 exhibits very low immunogenicity and high
resistance to exopeptidases (Maqueda et al., 1993).
The trypanocidal/leishmanicidal effect of AS-48 has been recently
described. In both cases, the negative surface charge of the parasites has
been related to the potent effect of AS-48. Although both parasites are
from the same family, different action mechanisms have been described
in each one (Abengózar et al., 2017; Martínez-García et al., 2018). The
activity of AS-48 against T. brucei is the highest described until now,
and it is because the high efficiency in the internalization of AS-48 by
the flagellar pocket of the parasite. Although both parasites are from
the same family, different action mechanisms have been described in
each one (Abengózar et al., 2017; Martínez-García et al., 2018). In this
study we report the in vitro activity of AS-48 against three different T.
cruzi strains (including one BZN-resistant), investigating the putative
mechanism of action. We have also demonstrated the low AS-48 cyto-
toxicity on uninfected Vero cells and the absence of pore-forming ac-
tivity in both Vero cells and T. cruzi. Finally, AS-48 is a fast-acting cidal
drug with an action mechanism that could be intermediate to those
observed in T. brucei and Leishmania spp. In T. cruzi the trypanocidal
activity could be mainly explained in a mitochondrion-dependent
manner through the production of reactive oxygen species (ROS) and
mitochondrial depolarization. In summary and according to with the
positive results achieved in this work, AS-48 is shaping up as a pro-
mising therapeutic agent against Chagas disease, although it will be
crucial to perform the in vivo studies, in order to know the effectiveness
in both acute and chronic phases of the disease.
2. Material and methods
2.1. AS-48 purification
Bacteriocin AS-48 was purified to homogeneity from cultures of the
Enterococcus faecalis UGRA10 strain (Ananou et al., 2008; Cebrián et al.,
2012) by chromatographic passes (cationic interchange and reversed-
phase high-performance liquid chromatography, RP-HPLC) as has been
previously described (Cebrián et al., 2015). The protein concentration
of the purified AS-48 was determined by measuring UV absorption at
280 nm a Nanodrop 2000 (Thermo Fisher Scientific. Waltham, MA,
USA).
2.2. Drug susceptibility assays against Vero cells and T. cruzi forms
2.2.1. Vero cells culture and cytotoxicity tests
Vero cells (EACC number 84113001) were cultured in RPMI
(Gibco®) with 10% (v/v) FBS heat-inactivated, at 37 °C in humidified
95% air and 5% CO2 atmosphere. Cytotoxicity tests were assessed using
the method previously described (Martín-Escolano et al., 2018) at do-
sages of 1000 to 1 μM of AS-48 and BZN. Briefly, cytotoxicity was tested
using 96-well microtiter plates by seeding the cells at 1.25×104mL−1.
After 24 h of incubation, the cells were treated with AS-48 and BZN in
0.2 mL volumes in RPMI (Gibco®) with 1% (v/v) FBS heat-inactivated
for 48 h. Subsequently, resazurin sodium salt (Sigma-Aldrich) was
added, the plates were incubated for a further 24 h, and finally the
trypanocidal activity was determined by absorbance measurements.
The trypanocidal effect, using GraphPad Prism 6, was expressed as the
inhibition concentration 50 (IC50), i.e., the concentration required to
result in 50% inhibition.
2.2.2. Epimastigote forms culture and in vitro activity assays
Three different T. cruzi strains were assessed: SN3 (IRHOD/CO/
2008/SN3); Arequipa (MHOM/Pe/2011/Arequipa); and Tulahuen
(TINF/CH/1956/Tulahuen), belonging to three discrete typing units
(DTUs), I, V and VI, respectively. Epimastigote forms were cultured at
28 °C in RPMI (Gibco®) with 10% (v/v) FBS heat-inactivated, 0.03M
hemin and 0.5% (w/v) trypticase (BBL) (Kendall et al., 1990).
For the trypanocidal test, epimastigote forms were centrifuged in
the exponential growth phase at 400 g for 10min. Trypanocidal activity
was determined according to the method previously described (Martín-
Escolano et al., 2018) at dosages ranged from 50 to 0.02 μM of AS-48
and BZN. Briefly, tests were carried out by seeding the parasites at
5× 105 mL-1 after adding AS-48 and BZN in 0.2 mL volumes in 96-well
microtiter plates at 28 °C for 48 h. Finally, resazurin sodium salt (Sigma-
Aldrich) was added, and after 24 h of incubation, the same procedure as
described in 2.2.1. Section was performed.
2.2.3. In vitro activity assays against intracellular amastigote forms
Trypanocidal activity against amastigote forms and the infectivity
index were determined according to the method previously described
(Martín-Escolano et al., 2018) at dosages of 50 to 0.02 μM of each drug.
Briefly, tests were performed in 24-well microtiter plates with rounded
coverslips by seeding the Vero cells at 1× 104 well−1 in RPMI (Gibco®)
with 10% (v/v) FBS heat-inactivated, at 37 °C in humidified 95% air
and 5% CO2 atmosphere. After 24 h of incubation, the cells were in-
fected with Vero cell-derived trypomastigotes at a multiplicity of in-
fection (MOI) ratio of 1:10. After 24 h, non-phagocyted parasites were
washed away, and after adding AS-48 and BZN in 0.5mL volumes in
RPMI (Gibco®) with 1% (v/v) FBS heat-inactivated. After 72 h of in-
cubation, the trypanocidal activity was assessed by analyzing 500 host
cells in methanol-fixed and Giemsa-stained preparations. The trypano-
cidal effect was determined using GraphPad Prism 6, as mentioned in
2.2.1. Section.
2.2.4. In vitro activity assays against extracellular bloodstream
trypomastigote forms
Epimastigote forms maintained at 28 °C were induced to transform
into metacyclic forms using Grace's Insect Medium (Gibco®), TAU and
TAU3AGG mediums following the method previously described
(Martín-Escolano et al., 2018). The obtained metacyclic trypomastigote
forms were used to infect Vero cells, and the obtained Vero cell-derived
trypomastigotes were used to infect BALB/c mice. Finally, bloodstream
trypomastigotes (BTs) were obtained by cardiac puncture during the
parasitaemia peak.
Trypanocidal activity was determined as described previously
(Martín-Escolano et al., 2018) in 96-well microtiter plates by seeding
the parasites at 2× 106mL−1 in RPMI (Gibco®) with 10% (v/v) FBS
heat-inactivated, and after addition of AS-48 and BZN at dosages of 100
to 0.2 μM in 0.2 mL volumes at 37 °C in humidified 95% air and 5% CO2
atmosphere. After 24 h of incubation, resazurin sodium salt (Sigma-
Aldrich) was added, and after another 4 h of incubation, the same
process as described in 2.2.1. Section was performed.
2.3. Permeability tests of the plasma membrane of Vero cells by trypan blue
The permeability of Vero cells was determined using 24-well mi-
crotiter plates by seeding the cells at 2× 105mL−1 after adding AS-48
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at dosages of 5-, 10- and 25-fold higher than IC50 in 0.5mL volumes at
37 °C in humidified 95% air and 5% CO2 atmosphere for 10, 30 and
60min. Untreated Vero cells and Vero cells exposed to 0.1% (v/v) and
0.01% (v/v) Triton X-100 (TX-100) were also included as negative and
positive controls, respectively. After incubations, Vero cells were col-
lected, and the plasma membrane permeability was determined by
adding trypan blue dye (Sigma-Aldrich) at 0.2% (final concentration) to
the cell suspension and counting using an optical microscope and a
hemacytometer counter.
2.4. Studies of the action mechanism
2.4.1. Determination of plasma membrane permeabilization by flow
cytometry using propidium iodide (PI)
Alterations in membrane permeability of T. cruzi Arequipa epi-
mastigote forms were detected by PI nucleic acid stain (Tiuman et al.,
2014; Bustos et al., 2017). Membrane permeability was determined in
1.5 mL microtubes by inoculating the parasites at 1×107mL−1 after
adding AS-48 at dosages of 10-, 20- and 50-fold higher than IC50 in
0.5 mL at 28 °C for 10, 30 and 60min. After incubations, epimastigote
forms were centrifuged, washed with PBS, and stained with 2 μg/mL PI
dye (Sigma-Aldrich) in 0.5 mL at 28 °C for 10min (Tiuman et al., 2014).
Non-stained parasites, untreated parasites and parasites exposed to
0.01% (v/v) and 0.1% (v/v) TX-100 as negative and positive controls
were also included. Finally, the parasites were collected, washed twice
with cold PBS, and resuspended in 1mL of cold PBS for fluorescence
measurements by flow cytometry in a BECTON DICKINSON FACSAria
III flow cytometer using a BECTON DICKINSON FACSDiva v8.01 soft-
ware (2350 Qume Drive, San Jose, Palo-Alto, California)
(λEXC= 488 nm, λEM=620 nm).
2.4.2. Metabolite excretion test by proton nuclear magnetic resonance (1H
NMR)
Cultures of epimastigote forms (5× 105mL−1) in cell culture flasks
were added of AS-48 at IC25 concentrations and then maintained at
28 °C for 72 h. Non-treated parasites (negative controls) were also in-
cluded. The supernatants were then collected by centrifugation at 800g
for 10min to determine the excreted metabolites by 1H NMR using a
VARIAN DIRECT DRIVE 400MHz Bruker spectrometer with an AutoX
probe using D2O as previously described (Fernández-Becerra et al.,
1997). The binning, normalizations and analyses were obtained using
Mestrenova 9.0 software.
2.4.3. Mitochondrial dysfunction tests
2.4.3.1. Rhodamine 123 (Rho) and acridine orange (AO) assays by flow
cytometry. The treated T. cruzi Arequipa epimastigote forms described
in 2.4.2. Section were centrifuged, washed twice with PBS, and stained
with 10 μg/mL Rho or AO dyes (Sigma-Aldrich) in 0.5 mL at 28 °C for
20min (Sandes et al., 2014). Non-stained parasites and untreated
parasites were also included as controls. After that, the parasites were
collected, washed twice with cold PBS, and resuspended in 1mL of cold
PBS for fluorescence measurements by flow cytometry in a BECTON
DICKINSON FACSAria III flow cytometer using a BECTON DICKINSON
FACSDiva v8.01 software (2350 Qume Drive, San Jose, Palo-Alto,
California). The fluorescence intensities for Rho (mitochondrial
membrane potential) and AO (nucleic acids) were measured as
described elsewhere (Sandes et al., 2014).
2.4.3.2. MitoSOX™ Red assays by flow cytometry. Cultures of T. cruzi
Arequipa epimastigote forms (1× 107mL−1) in 1.5 mL microtubes
were stained with 0.5 μM MitoSOX™ Red dye (Invitrogen) in 0.5mL at
28 °C for 30min (Abengózar et al., 2017), and washed twice with PBS
before the assay (Piacenza et al., 2007). AS-48 was added at 5 μM
(Abengózar et al., 2017) at 28 °C for 10, 30 and 60min. Non-stained
parasites, untreated parasites and parasites exposed to 200 μM
hydrogen peroxide were also included. Finally, epimastigote forms
were processed as described in 2.4.1. Section to measure the
fluorescence intensity for oxMitoSOX (ROS production)
(λEXC= 510 nm, λEM=580 nm) (Piacenza et al., 2007).
2.5. Statistical analyses
Data were recorded on a Microsoft Excel spreadsheet, and statistical
analyses were performed by using IBM SPSS Statistics software (v. 21).
The t-test for paired samples was used to verify whether there were
differences between the assays used, with p < 0.05 considered statis-
tically significant and with a 95% confidence level. Also statistical
studies based on contingency tables (prevalence) were conducted, to-
gether with the× 2 test of the relationship between variables.
3. Results and discussion
3.1. AS-48 effects over T. cruzi growth in vitro
Currently, the genetic diversity of T. cruzi is extensively known
being the parasite classified into seven DTUs that show different evo-
lutionary relationships, epidemiological and ecological associations,
tropism, pathogenesis, genotype, phenotype, and drug resistance
(Zingales, 2018). Different concentrations of purified AS-48 bacteriocin
(50–0.02 μM) were assayed against extracellular epimastigote, trypo-
mastigote and intracellular amastigote forms of three strains of T. cruzi
belonging to different DTUs – SN3, Tc I; Arequipa, Tc V; and Tulahuen,
Tc VI – to evaluate its inhibitory activity using BZN as the reference.
The IC50 values are presented in Table 1. Toxicity of AS-48 and BZN
against uninfected Vero cells was also tested in parallel (Table 1), and
the selectivity index (SI) (SI = IC50 Vero cells/IC50 extra- and in-
tracellular forms) (Table 2) against T. cruzi was calculated.
In the case of the epimastigote forms, the IC50/72 h values ranged
between 0.76 μM for the Arequipa strain and 1.16 μM for the BZN re-
sistant SN3 strain. These values were 22, 31 and 24-fold lower for
Arequipa, SN3 and Tulahuen strains (respectively), than the values
obtained for BZN.
Regarding the amastigote forms the relationship between the IC50/
72 h of BZN/AS-48 was lower (8, 2 and 5-fold) due to the minor sus-
ceptibility of these forms. The strains Arequipa and Tuhaluen were the
most sensitive to AS-48 (0.99 and 1.98 μM respectively) while the strain
Table 1
Trypanocidal activity of AS-48 and BZN on the three developmental forms of T. cruzi strains. Toxicity on Vero cells.
Comp. Activity IC50 (μM)a Activity IC50 (μM)a Activity IC50 (μM)a Toxicity IC50/72 h
(μM)
Vero cellArequipa strain SN3 strain Tulahuen strain
E/72 h A/72 h T/24 h E/72 h A/72 h T/24 h E/72 h A/72 h T/24 h
BZN 16.86 ± 1.81 8.25 ± 0.72 12.35 ± 1.14 36.51 ± 2.44 16.62 ± 1.46 36.09 ± 3.12 19.72 ± 1.75 9.96 ± 0.84 15.09 ± 1.30 80.35 ± 7.08
AS-48 0.76 ± 0.11 0.99 ± 0.13 0.17 ± 0.04 1.16 ± 0.18 6.81 ± 0.89 0.11 ± 0.02 0.82 ± 0.11 1.98 ± 0.22 0.19 ± 0.03 93.06 ± 5.67
a IC50= concentration (μM) required to inhibit 50% population, calculated using GraphPad Prism 6. Results are averages of three separate determinations ±
standard deviation. E, epimastigote forms. A, amastigote forms. T, trypomastigote forms.
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SN3 showed a higher resistance (6.81 μM). We suggest that this could
be due to AS-48 has to cross many membranes to reach the parasite, and
the intracellular environment may not be the most appropriate for the
AS-48 activity.
Finally, the trypomastigote forms were also susceptible to AS-48
treatment with the lower IC50/24 h: 0.17, 0.11 and 0.19 μM against
Arequipa, SN3 and Tulahuen strains, respectively, while BZN needed
12.35, 36.09 and 15.09 μM, respectively. Interesting, these forms were
more the most resistant to BZN (not in the case of Arequipa) (Table 1)
with an IC50/24 h BZN/AS-48 ratio of 73, 328, and 79. The high AS-48
activity observed in these forms could be due to the characteristics of
their membranes, which are composed mostly of phosphatidyl-choline
and to a lesser extent of phosphatidyl-ethanol-amine (Agusti et al.,
2000).
It is remarkable that BTs and intracellular amastigote forms are the
most interesting forms from a clinical point of view (González et al.,
2005) being in all cases sensitive to a low micromolar range of AS-48. In
general, the IC50 observed for these forms were lower than the activity
observed in the case of Leishmania spp. (IC50 of 4 μM and 10.2 μM for L.
donovani and L. pifanoi promastigotes and amastigotes respectively).
However, these IC50 were higher than in the case of T. brucei
(1.7–3.12 nM) probably due to the fact that AS-48 is not able to enter
inside T. cruzi as fast as in T. brucei. In fact, in the procyclic form of T.
brucei or in the blood forms at 4 °C (when the parasite endocytic-
membrane activity is stopped), the IC50 obtained for T. brucei were
closed to the values obtained for T. cruzi (Martínez-García et al., 2018).
These data make us think that the mechanism of action, in this case,
could be intermediate between Leishmania spp. and T. brucei.
Furthermore, the toxicity towards Vero cells was also assayed. In
this case, the IC50/72 h was higher for AS-48 (93.06 μM) than for BZN
(80.35 μM) (Table 1). The calculated AS-48 IC50 toward these cells
confirmed, together with the IC50 values against the different forms of
the parasite, a high selectivity index for the different morphological
forms of T. cruzi tested, much better than the selectivity index observed
for BZN (Table 2).
Moreover, to obtain accurate information about the AS-48 trypa-
nocidal activity, in vitro infection on Vero cells and treatment with AS-
48 was performed. The rate of infection of T. cruzi Arequipa strain was
measured by counting infected cells after 72 h of exposure at different
concentrations of AS-48. The data are shown in Fig. 1, together with the
data of amastigote and trypomastigote forms. It was found that the rates
of infected cells decreased as the concentrations of AS-48 increased,
with an IC50/72 h of 2.62 μM (6-fold lower than for BZN). Likewise, the
total number of amastigote and trypomastigote forms decreased more
for AS-48-treated cultures than for those treated with BZN.
The average number of amastigote forms per cell was also measured
at different concentrations (Fig. 2), giving an idea of the killing rate.
The data show that AS-48 is faster acting than BZN, which is considered
until now as a fast-acting compound (Chatelain, 2015). These data
show that AS-48 not only inhibits the parasite multiplication (static
compound) but also causes its death (cidal compound). These features
are additional advantages since fast-acting trypanocidal drugs can
Table 2
Selectivity Index for AS-48 and BZN on extra- and intracellular forms of T. cruzi strains.
Comp. Selectivity index Selectivity index Selectivity index
Arequipa straina SN3 straina Tulahuen straina
E A T E A T E A T
BZN 4.77 9.73 6.51 2.20 4.83 2.23 4.07 8.07 5.32
AS-48 122.45 94.00 547.41 80.22 13.67 846.00 113.49 47.00 489.79
AS-48/BZNb 26 10 84 36 3 379 28 6 92
a Selectivity index (SI)= IC50 Vero cells/IC50 extracellular and intracellular form of parasite. bNumber of times that AS-48 exceeds the reference drug SI (on
extracellular and intracellular forms of T. cruzi). E, epimastigote forms. A, amastigote forms. T, trypomastigote forms.
Fig. 1. Reduction of the infection of T. cruzi Arequipa strain regarding the
decrease of amastigote and trypomastigote forms and infected cells treated with
(a) BZN and (b) AS-48. Values are the means of three separate experi-
ments ± standard deviation. In brackets: IC50 value, calculated using
GraphPad Prism 6.
Fig. 2. Reduction in the number of amastigote forms of T. cruzi Arequipa strain
per Vero cell treated with BZN and AS-48 for 72 h. Values are the means of
three separate experiments ± standard deviation. Significant differences be-
tween the BZN and AS-48 for α=0.05.
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eliminate the parasite in a few doses (Rycker et al., 2012).
It is noticeable that in amastigote forms AS-48 has to go inside the
cell to kill the parasite crossing the decks that surround it. This is the
first time that has been reported activity for AS-48 inside of non-im-
mune cells (different to macrophage in the case of Leishmania spp). In
order to elucidate how AS-48 can enter into the Vero cells, a perme-
ability membrane assay was performed at different AS-48 concentra-
tions and exposure times, using TX-100 as control (Fig. 3 and SFig. 1).
The tested AS-48 concentrations were higher than the IC50 obtained
(Table 1) because the incubation times were shorter and a higher
number of Vero cells were used for the test. The data show that AS-48
did not disrupt the Vero cells membranes at concentrations as high as 5-
and 10-fold higher than IC50 – 191 and 382 μM, respectively – at 10 and
30min and barely at 60min, suggesting that AS-48 does not cause pores
in spite of the high concentrations tested. Only those concentration very
high tested (25-fold higher than IC50, which is clote to 1mM) seem to
alter the Vero cells membranes, and never at the concentrations tested –
50 to 0.2 μM – in the activity assays against intracellular amastigote
forms. With these results, the mechanism by which AS-48 can enter in
the cell, without affect the integrity of the membrane barrier, and being
able to kill the parasite, remains uncertain. However, one possibility is
the cellular depolarization mechanism induced by cationic peptides
when they are used at relevant concentrations, facilitating their entry
through the membranes and activity on internal targets (Hale and
Hancock, 2007).
Overall, these in vitro assays showed that AS-48 is a fast-acting and
cidal agent that presents an excellent trypanocidal activity independent
of the form and strain of the T. cruzi used, with higher activity and
lower cytotoxicity than BZN. Moreover, AS-48 meets the in vitro criteria
to be considered as a potential antichagasic agents: IC50≤ 10 μM, and
SI > 10 (Don and Ioset, 2014); or IC50< 5 μM, SI> 10, and the ma-
jority of the in vitro criteria of the target product profile (TPP)
(Chatelain, 2015).
3.2. Studies about the mechanism of action
3.2.1. AS-48 effects over T. cruzi plasma membrane pore-formation
According to the bactericidal and leishmanicidal mechanism of ac-
tion described for AS-48, the primary target is the cell membrane where
AS-48 forms pores (Sánchez-Barrena et al., 2003; Abengózar et al.,
2017). To confirm if the fast-acting cidal effect observed for AS-48 on T.
cruzi is also due to the formation of pores in the membrane, perme-
ability assay of the plasma membrane of T. cruzi was performed by flow
cytometry. We used PI stain after treating the parasites at different AS-
48 concentrations and times of exposure, and TX-100 as positive control
(Fig. 4 and SFig. 2). The AS-48 concentrations tested were higher than
the IC50 obtained (Table 1) because the incubation times were shorter
and more epimastigote forms were used. Collectively the data indicate
that AS-48 did not permeate the T. cruzi plasma membrane at any of the
concentrations (5-, 20- and 50-fold higher than IC50 – 3.8, 15.2 and
38 μM, respectively –) and incubation times tested, and therefore AS-48
must subject T. cruzi to a fast-acting cell death mechanism that differs
from the pore formation. This suggests that as in T. brucei, AS-48 should
enter in the parasite by endocytosis that in T. cruzi is restricted to two
specialized invaginations of the plasma membrane, the flagellar pocket,
and the cytostome (De Souza, 2008). Unlike T. brucei bloodstream
forms, in which the endocytic turnover of the surface is exceptionally
high, in T. cruzi the endocytic rate is much lower (Porto-Carreiro et al.,
2000). The lower endocytic level has been also observed in amastigote
forms, which could also be related to the higher resistance to AS-48
(Batista et al., 2015). Besides, cytostome is not present in trypomasti-
gote forms (De Souza, 2008; Vidal et al., 2016), that according to our
results are the most susceptible form. Therefore, the main route of entry
of AS-48 into the cell should be the flagellar pocket.
The study of the mechanism of action at the energy metabolism
level was evaluated. Alteration of metabolites excretion (glycosomal
level) and also mitochondrial dysfunction (mitochondrial level) were
prompted for three reasons: a) the strong AS-48 fast-acting trypanocidal
effect (in the absence of a plasma membrane permeabilization) that can
be caused by a fast and severe bioenergetic collapse, b) the single mi-
tochondrion of T. cruzi, a likely target for AS-48 due to its evolutionary
resemblance with bacteria, and c) the presence of cardiolipin, a typical
mitochondrial phospholipid that interacts strongly with AS-48 (Gálvez
et al., 1989).
3.2.2. Metabolite excretion
It is well-known that T. cruzi is unable to completely degrading
glucose to CO2 in aerobic environments, catabolizes glucose at a high
rate, and acidifies the medium owing to incomplete oxidation to acids
like pyruvate, acetate and succinate, among others (Bringaud et al.,
2006). Consistently, to know the effect of AS-48 on glucose metabolism,
1H NMR spectra of the medium of AS-48-treated epimastigote forms
were qualitatively and quantitatively analyzed and compared with the
spectra found for the untreated parasites (Fig. 5). The excretion of all
metabolites in the three AS-48-treated T. cruzi strains was strikingly
reduced concerning the corresponding untreated parasites. Therefore, a
deficit in the production of catabolites by a blocking in the glycolytic
pathway seems to be caused by AS-48. This alteration could be asso-
ciated with an inhibition in the first enzymes involved in this pathway
(glycosomal level) or to a mitochondrial dysfunction (mitochondrial
level) that can produce an imbalance in the NADH/NAD+ and ATP/
Fig. 3. Permeabilization of the plasma membrane of Vero cells treated with TX-
100 and AS-48 for 10 min, 30 min and 60 min. Values are the means of the
three separate determinations ± standard deviation. * Significant differences
between untreated and treated Vero cells for α = 0.05.
Fig. 4. Permeabilization of the plasma membrane of epimastigote forms of T.
cruzi Arequipa strain treated with TX-100 and AS-48 for 10 min, 30 min and
60 min. Values are the means of the three separate determinations ± standard
deviation. * Significant differences between untreated and treated parasites for
α = 0.05.
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ADP ratios causing a blockade in the glycolytic pathway (Bringaud
et al., 2006; Wen et al., 2010).
3.2.3. Mitochondrial dysfunction
Hence, to assess if the alteration in the glycolytic pathway is a
consequence of a mitochondrial dysfunction, flow cytometry analysis of
the membrane potential and ROS production from treated parasites was
performed using Rho and MitoSOX™ Red as fluorescents, respectively
(Fig. 6, Fig. 7 and SFig. 3).
Regarding the mitochondrial membrane potential assay (Fig. 6), we
confirmed that BZN-treated parasites showed a decrease in mitochon-
drial membrane potential (35.38%) because it is known that BZN kills
T. cruzi through its transformation to highly reactive metabolites after
reduction by type I nitroreductase activity (Hall and Wilkinson, 2012),
causing, among others, respiratory chain inhibition. Interestingly, for
AS-48, the treated parasites also showed a decrease in mitochondrial
membrane potential (30.68%) despite having used a lower concentra-
tion (the IC25).
Regarding the ROS production assay (Fig. 7 and SFig. 3), AS-48
treated parasites at 5 μM showed significant ROS production from
10min of exposure (35.65%), being even higher than the parasites
treated with H2O2, and increasing to more than 50% at 60min of ex-
posure.
3.2.4. Nucleic acids levels
The mitochondrion plays a crucial role in cell death decisions, and
alterations in the integrity and function of it lead to a decrease in ATP
production and nucleic acids levels, inducing apoptosis or necrosis (Lee
and Thévenod, 2006; Shang et al., 2009). Therefore, the alterations
observed in the integrity and function of the mitochondrion can lead to
a decrease in ATP production and nucleic acids levels, inducing apop-
tosis or necrosis (Lee and Thévenod, 2006; Shang et al., 2009). Con-
sequently, to determine the nucleic acids levels, flow cytometry ana-
lyses were performed using AO as fluorescent (Fig. 8). Remarkably, BZN
and AS-48-treated parasites showed similar decreases in the AO fluor-
escence intensity (22.38% and 16.97%, respectively), as a consequence
of the reduction in the amount of nucleic acids. It must be noted that
the decrease in nucleic acids levels is also due to random nucleic acids
degradation as commonly attributed feature to cell necrosis, and not
only because of the APT deficit (Verma et al., 2007).
Accordingly, the putative mechanism of action for AS-48 could be
explained in a mitochondrion-dependent manner through a mitochon-
drial depolarization and ROS production that causes a fast collapse in
the energy metabolism of T. cruzi, as has been described in Leishmania
Fig. 5. Variation (percentages) among peaks of catabolites excreted by T. cruzi
epimastigote forms exposed to AS-48 at their IC25 in comparison to the control
(untreated) incubated 72 h. Values are the means of three separate determi-
nations ± standard deviation. Significant differences between the control and
AS-48 for α=0.05.
Fig. 6. Cytometry analysis of the mitochondrial membrane potential from
epimastigotes of T. cruzi Arequipa strain exposed to BZN and AS-48 at their IC25
in comparison to the control (untreated) incubated 72 h: (a) blank, (b) control
(untreated), (c) BZN and (d) AS-48. Each drug was tested in three separate
determinations. In brackets: reduction, in percentage, in the mitochondrial
membrane potential with respect to untreated parasites. Significant differences
between untreated parasites and parasites treated with BZN and AS-48 for
α=0.05.
Fig. 7. Production of mitochondrial ROS of epimastigote forms of T. cruzi
Arequipa strain exposed to H2O2 and AS-48 at 200 μM and 5 μM, respectively,
for 10 min, 30 min and 60 min. Values are the means of the three separate
determinations ± standard deviation. * Significant differences between un-
treated and treated parasites for α = 0.05.
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spp. (Abengózar et al., 2017). However, the AS-48 leishmanicidal ac-
tivity is also produced by a partial plasma membrane permeabilization
(Abengózar et al., 2017), a mechanism that does not happen in T. cruzi.
We suggest that AS-48 should be endocytosed by the flagellar pocket.
Moreover, the fact that intracellular amastigotes show a lower en-
docytosis activity than extracellular forms (Nogueira et al., 2015) also
support their lower susceptibility of these to AS-48.
As AS-48 is a stable peptide that exhibits very low immunogenicity
and high resistance to exopeptidases, it could be a promising drug
against Chagas disease. Further validation of the usefulness of AS-48 in
this field requires murine model assays to determine the in vivo trypa-
nocidal activity of AS-48 during both the acute and chronic phases.
Moreover, biochemical analysis will be performed in order to know the
possible abnormalities associated with the treatments.
4. Conclusions
In conclusion, the trypanocidal properties of AS-48 were examined,
and the experiments allowed us to present AS-48 as a promising al-
ternative for the development of a new therapeutic agent against CD.
AS-48 showed enhanced efficiency and lower toxicity than the re-
ference drug BZN, and a broader spectrum of action. Finally, the action
mechanism whereby AS-48 shows a fast-acting cidal effect against T.
cruzi is mitochondrion-dependent through a ROS production and mi-
tochondrial membrane depolarization, causing a fast and severe bioe-
nergetic collapse. Interesting AS-48 has also displayed antiparasitic
activity against amastigote forms (inside Vero cells) in a low micro-
molar range. This means that AS-48 has to enter in the cell to kill the
parasite, being the first time that this kind of activity has been reported
for a bacteriocin in non-defensive immune cells.
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